Novel Synthesis of the Hexahydroimidazo[1,5b]isoquinoline Scaffold: Application to the Synthesis of Glucocorticoid Receptor Modulators
摘要:
The first stereoselective synthesis of the hexahydroimidazo[1,5b]isoquinoline (HHII) scaffold as a surrogate for the steroidal A-B ring system is described. The structure - activity relationships of the analogs derived from this scaffold show that the basic imidazole moiety is tolerated by the glucocorticold receptor (GR) in terms of binding affinity, although the partial agonist activity in the transrepressive assays depends on the substitution pattern on the B-ring. More importantly, most compounds in the HHII series bearing a tertiary alcohol moiety on the B-ring are either inactive or significantly less active in inducing GR-mediated transactivation, thus displaying a "dissociated" pharmacology in vitro.
Novel Synthesis of the Hexahydroimidazo[1,5b]isoquinoline Scaffold: Application to the Synthesis of Glucocorticoid Receptor Modulators
摘要:
The first stereoselective synthesis of the hexahydroimidazo[1,5b]isoquinoline (HHII) scaffold as a surrogate for the steroidal A-B ring system is described. The structure - activity relationships of the analogs derived from this scaffold show that the basic imidazole moiety is tolerated by the glucocorticold receptor (GR) in terms of binding affinity, although the partial agonist activity in the transrepressive assays depends on the substitution pattern on the B-ring. More importantly, most compounds in the HHII series bearing a tertiary alcohol moiety on the B-ring are either inactive or significantly less active in inducing GR-mediated transactivation, thus displaying a "dissociated" pharmacology in vitro.
NONSTEROIDAL COMPOUNDS USEFUL AS MODULATORS OF GLUCOCORTICOID RECEPTOR AP-1 AND/OR NF-KAPPAB ACITIVITY AND USE THEREOF
申请人:Dhar T.G. Murali
公开号:US20110263494A1
公开(公告)日:2011-10-27
Disclosed are compounds of Formula (I) wherein: one of A and D is —N— and the other of A and D is —C—; or enantiomers, diastereomers, or pharmaceutically-acceptable salts thereof. Also disclosed are methods of using such compounds to modulate the function of glucocorticoid receptor activity and pharmaceutical compositions comprising such compounds.
NONSTEROIDAL COMPOUNDS USEFUL AS MODULATORS OF GLUCOCORTICOID RECEPTOR AP-1 AND/OR NF- KAPPA B ACTIVITY AND USE THEREOF
申请人:Bristol-Myers Squibb Company
公开号:EP2209780B1
公开(公告)日:2014-01-01
US8309730B2
申请人:——
公开号:US8309730B2
公开(公告)日:2012-11-13
[EN] NONSTEROIDAL COMPOUNDS USEFUL AS MODULATORS OF GLUCOCORTICOID RECEPTOR AP-1 AND/OR NF-?B ACTIVITY AND USE THEREOF<br/>[FR] COMPOSÉS NON STÉROÏDIENS UTILES EN TANT QUE MODULATEURS DE L'ACTIVITÉ AP-1 ET/OU NF-?B DU RÉCEPTEUR DES GLUCOCORTICOÏDES ET LEUR UTILISATION
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2009058944A2
公开(公告)日:2009-05-07
Disclosed are compounds of Formula (I) wherein: one of A and D is -N- and the other of A and D is -C-; or enantiomers, diastereomers, or pharmaceutically-acceptable salts thereof. Also disclosed are methods of using such compounds to modulate the function of glucocorticoid receptor activity and pharmaceutical compositions comprising such compounds.
Novel Synthesis of the Hexahydroimidazo[1,5b]isoquinoline Scaffold: Application to the Synthesis of Glucocorticoid Receptor Modulators
作者:Hai-Yun Xiao、Dauh-Rurng Wu、Mary F. Malley、Jack Z. Gougoutas、Sium F. Habte、Mark D. Cunningham、John E. Somerville、John H. Dodd、Joel C. Barrish、Steven G. Nadler、T. G. Murali Dhar
DOI:10.1021/jm901551w
日期:2010.2.11
The first stereoselective synthesis of the hexahydroimidazo[1,5b]isoquinoline (HHII) scaffold as a surrogate for the steroidal A-B ring system is described. The structure - activity relationships of the analogs derived from this scaffold show that the basic imidazole moiety is tolerated by the glucocorticold receptor (GR) in terms of binding affinity, although the partial agonist activity in the transrepressive assays depends on the substitution pattern on the B-ring. More importantly, most compounds in the HHII series bearing a tertiary alcohol moiety on the B-ring are either inactive or significantly less active in inducing GR-mediated transactivation, thus displaying a "dissociated" pharmacology in vitro.